Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome

What Was Tested

Researchers studied Alpha-MSH and Setmelanotide in this randomized controlled trial publication.

Here, MetS-Z-BMI scores, a continuous measure based on body mass index (BMI), were calculated to determine metabolic syndrome severity and response to treatment with the melanocortin-4 receptor agonist setmelanotide in BBS.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

All patients from a phase 3 study (NCT03746522) of setmelanotide with data required for the calculation of MetS-Z-BMI scores were included.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Alpha-MSH study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Mean MetS-Z-BMI score was determined at baseline and Week 52; subgroup analyses were conducted by sex, age, genotype, and response to setmelanotide.

What Was Measured

The subject headings attached to it are Metabolic Syndrome, Bardet-Biedl Syndrome, alpha-MSH, Body Mass Index, Receptor, Melanocortin, Type 4, Risk Factors and Obesity.

The authors tagged it with the keywords cardiovascular disease, comorbidities, genetics/genomics, hypothalamus and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized study of Alpha-MSH and Setmelanotide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Alpha-MSH compound page and the Setmelanotide compound page, all human trials.